ThromboVision

ThromboVision, Inc. was a biomedical diagnostics company founded in 2005 and based in Houston, Texas. The company focused on developing point-of-care clinical diagnostic products for hematology.

The firm's lead product was the ThromboGuide™, a point-of-care device designed to enable physicians to personalize and monitor anti-coagulation therapies to prevent heart attacks, strokes, and stent occlusions. This system, which consisted of a disposable test kit and a point-of-care analyzer, was intended to monitor the effectiveness of widely prescribed antiplatelet medications like Aspirin and Plavix. The technology was licensed from scientists affiliated with the Utah Artificial Heart Research Institute, Brigham Young University, and the University of Utah. The President and CEO was Edward R. Teitel.

ThromboVision raised a total of $4 million in funding over two rounds, including a Series A financing round and a conventional debt round. The company initiated clinical trials for its ThromboGuide™ system to support its 510(k) application to the Food and Drug Administration (FDA) and its application for a CLIA waiver, which would allow the tests to be conducted in non-laboratory settings like physicians' offices. Despite winning the first annual Michael E. DeBakey Life Science Award, the company filed for bankruptcy in September 2010 and is now considered deadpooled.

Keywords: point-of-care diagnostics, hematology, anti-coagulation therapy, platelet function analyzer, ThromboGuide, cardiovascular risk assessment, blood clot prevention, antiplatelet medication monitoring, biomedical diagnostics, clinical diagnostic products, medical device, heart attack prevention, stroke prevention